Signaling is fundamental to how cells sense and respond to their environment—but in immune cells, those signals must be ...

Chimeric antigen receptor T-cell therapy—CAR T for short—has been a major advance in treating blood cancers like leukemia and ...

Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...

A new CAR T-cell therapy attacks supportive cells in the tumor microenvironment that bear the surface protein, uPAR.

T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on exquisitely timed molecular signals. Now researchers have captured one of the ...

In a new study published in GEN’s sister peer-review journal, GEN Biotechnology, titled, “Exploring Structure-Function Relationships in Engineered Receptor Performance Using Computational Structure ...

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack ...

Cancer immunotherapy, especially using T cells, is showing a lot of promise in treating blood cancers. Bioengineered T cells, especially those equipped with chimeric antigen receptors (CAR-T cells), ...

Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks.

Preclinical research has shown that CAR T cells directed against the urokinase plasminogen activator receptor can attack both ...